Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Book
| HROW - Harrow Health | 25.24% | Hold | 3,905,000 | $49.00 | $191M | — | — |
| LQDA - Liquidia | 11.21% | Reduce −6.9% | 2,435,000 | $34.90 | $85M | −180,000 | +$26M |
| ETON - Eton Pharmaceuticals | 6.38% | Hold | 2,860,000 | $16.91 | $48M | — | — |
| RYTM - Rhythm Pharmaceuticals | 4.66% | Reduce −28.5% | 330,000 | $107.04 | $35M | −131,700 | −$11M |
| APGE - Apogee Therapeutics | 3.87% | Add +6.9% | 388,257 | $75.48 | $29M | +25,000 | +$15M |
| SNWV - Sanuwave Health | 3.86% | Add +0.1% | 981,267 | $29.84 | $29M | +1,267 | −$7M |
| STOK - Stoke Therapeutics | 2.91% | Add +1.9% | 695,000 | $31.74 | $22M | +12,983 | +$6M |
| OCUL - Ocular Therapeutix | 2.55% | Hold | 1,595,000 | $12.14 | $19M | — | — |
| SLGL - Sol Gel Technologies | 2.52% | Add +121.5% | 453,739 | $42.14 | $19M | +248,904 | +$13M |
| CGON - Cg Oncology | 2.25% | Hold | 410,000 | $41.52 | $17M | — | — |
| TGTX - Tg Therapeutics | 2.10% | Hold | 535,000 | $29.81 | $16M | — | — |
| IRON - Disc Medicine | 2.10% | Add +3.2% | 200,000 | $79.41 | $16M | +6,227 | +$3M |
| RZLT - Rezolute | 1.96% | Add +595.9% | 6,287,156 | $2.36 | $15M | +5,383,714 | +$6M |
| CBIO - Crescent Biopharma | 1.84% | New | 1,178,300 | $11.86 | $14M | +1,178,300 | +$14M |
| ALKS - Alkermes | 1.81% | Add +8.9% | 490,000 | $27.98 | $14M | +40,000 | +$210K |
| ACOG - Alpha Cognition | 1.78% | Add +1698.5% | 2,070,784 | $6.50 | $13M | +1,955,642 | +$13M |
| ANNX - Annexon | 1.72% | Hold | 2,600,000 | $5.02 | $13M | — | — |
| EWTX - Edgewise Therapeutics | 1.64% | Hold | 500,000 | $24.82 | $12M | — | — |
| CDXS - Codexis | 1.46% | Reduce −46.9% | 6,789,738 | $1.63 | $11M | −6,005,262 | −$20M |
| PTGX - Protagonist Therapeutics | 1.21% | Hold | 105,000 | $87.34 | $9M | — | — |
| Gossamer Bio | 1.11% | Reduce −0.2% | 2,720,000 | $3.10 | $8M | −5,000 | +$1M |
| MBX - Mbx Biosciences | 1.08% | Add +2.8% | 260,000 | $31.54 | $8M | +7,000 | +$4M |
| RVMD - Revolution Medicines | 1.05% | Hold | 100,000 | $79.65 | $8M | — | — |
| XOMA - XOMA Del | 1.03% | Add +14.7% | 292,590 | $26.59 | $8M | +37,503 | −$2M |
| DERM - Journey Medical | 0.99% | Add +0.4% | 975,000 | $7.71 | $8M | +3,936 | +$603K |
| KPTI - Karyopharm Therapeutics | 0.90% | New | 930,000 | $7.36 | $7M | +930,000 | +$7M |
| JBIO - Jade Biosciences | 0.87% | New | 427,608 | $15.43 | $7M | +427,608 | +$7M |
| URGN - Urogen Pharma | 0.83% | New | 268,423 | $23.42 | $6M | +268,423 | +$6M |
| ALMS - Alumis | 0.69% | Reduce −19.5% | 535,000 | $9.76 | $5M | −130,000 | +$3M |
| CATX - Perspective Therapeutics | 0.66% | New | 1,184,500 | $4.21 | $5M | +1,184,500 | +$5M |
| VYGR - Voyager Therapeutics | 0.62% | New | 1,196,904 | $3.93 | $5M | +1,196,904 | +$5M |
| RLMD - Relmada Therapeutics | 0.60% | New | 935,000 | $4.83 | $5M | +935,000 | +$5M |
| TECX - Tectonic Therapeutics | 0.59% | New | 214,747 | $20.86 | $4M | +214,747 | +$4M |
| PLX - Protalix Biotherapeutics | 0.59% | Reduce −4.0% | 2,478,176 | $1.80 | $4M | −102,380 | −$1M |
| TRVI - Trevi Therapeutics | 0.57% | Reduce −11.5% | 345,100 | $12.52 | $4M | −44,900 | +$752K |
| FBIO - Fortress Biotech | 0.53% | New | 1,090,000 | $3.66 | $4M | +1,090,000 | +$4M |
| RCKT - Rocket Pharmaceuticals | 0.44% | New | 955,000 | $3.51 | $3M | +955,000 | +$3M |
| MGTX - Meiragtx | 0.41% | New | 390,844 | $7.95 | $3M | +390,844 | +$3M |
| RIGL - Rigel Pharmaceuticals | 0.40% | Add +85.2% | 70,000 | $42.83 | $3M | +32,213 | +$2M |
| Zymeworks | 0.38% | Add +8.9% | 108,929 | $26.33 | $3M | +8,929 | +$1M |
| Assertio | 0.34% | New | 285,000 | $9.07 | $3M | +285,000 | +$3M |
| Ventyx Biosciences | 0.30% | New | 251,932 | $9.03 | $2M | +251,932 | +$2M |
| IRD - Opus Genetics | 0.30% | Add +1.8% | 1,120,000 | $2.01 | $2M | +20,000 | +$436K |
| STRO - Sutro Biopharma | 0.29% | New | 190,671 | $11.57 | $2M | +190,671 | +$2M |
| CABA - Cabaletta Bio | 0.26% | Add +11.3% | 900,000 | $2.19 | $2M | +91,118 | +$78K |
| ZNTL - Zentalis Pharmaceuticals | 0.25% | Add +342.6% | 1,400,906 | $1.35 | $2M | +1,084,356 | +$1M |
| Generation Bio | 0.23% | New | 310,000 | $5.68 | $2M | +310,000 | +$2M |
| BBIO - Bridgebio Pharma | 0.18% | New | 18,319 | $76.49 | $1M | +18,319 | +$1M |
| ENTA - Enanta Pharmaceuticals | 0.16% | New | 75,000 | $15.77 | $1M | +75,000 | +$1M |
| QTTB - Q32 Bio | 0.09% | New | 213,363 | $3.32 | $708K | +213,363 | +$708K |
| AVIR - Atea Pharmaceuticals | 0.08% | New | 179,815 | $3.57 | $642K | +179,815 | +$642K |
| Silence Therapeutics | 0.06% | New | 78,926 | $6.08 | $480K | +78,926 | +$480K |
| Rapt Therapeutics | 0.03% | New | 150,000 | $1.42 | $213K | +150,000 | +$213K |
| ADGM - Adagio Med | 0.02% | Hold | 110,571 | $1.04 | $115K | — | — |
Showing top 50 of 54 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q3
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Immunome | 5.27% | Exit | 0 | $11.71 | $37M | −3,185,000 | −$37M |
| Sarepta Therapeutics | 1.59% | Exit | 0 | $19.27 | $11M | −585,000 | −$11M |
| LRMR - Larimar Therapeutics | 1.49% | Exit | 0 | $2.84 | $11M | −3,720,867 | −$11M |
| ARVN - Arvinas | 1.19% | Exit | 0 | $8.52 | $8M | −987,818 | −$8M |
| Treace Medical Concepts | 0.67% | Exit | 0 | $6.71 | $5M | −702,245 | −$5M |
| ADCT - ADC Therapeutics SA | 0.39% | Exit | 0 | $4.00 | $3M | −682,529 | −$3M |
| SYRE - Spyre Therapeutics | 0.15% | Exit | 0 | $16.75 | $1M | −65,000 | −$1M |
| PEPG - Pepgen | 0.05% | Exit | 0 | $4.63 | $347K | −75,000 | −$347K |
| IBIO — | 0.04% | Exit | 0 | $0.8267 | $310K | −375,000 | −$310K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2